Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Gemcitabine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 574 Carcinoma, Non-Small-Cell Lung 270 Breast Neoplasms 136 Neoplasms 134 Urinary Bladder Neoplasms 132 Lung Neoplasms 131 Neoplasm Metastasis 115 Cholangiocarcinoma 94 Ovarian Neoplasms 82 Biliary Tract Neoplasms 75 Nasopharyngeal Carcinoma 63 Lymphoma, Large B-Cell, Diffuse 63 Lymphoma 56 Recurrence 54 Sarcoma 53 Gallbladder Neoplasms 52 Carcinoma, Transitional Cell 43 Hodgkin Disease 42 Colorectal Neoplasms 41 Lymphoma, Non-Hodgkin 39 Triple Negative Breast Neoplasms 38 Adenocarcinoma 38 Fallopian Tube Neoplasms 37 Bile Duct Neoplasms 36 Non-Muscle Invasive Bladder Neoplasms 27 Carcinoma 27 Uterine Cervical Neoplasms 26 Carcinoma, Ovarian Epithelial 26 Unspecified Adult Solid Tumor, Protocol Specific 24 Urethral Neoplasms 22

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡